Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab for maintenance in ANCA-associated vasculitis
NCT01663623Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2013
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) comparing Belimumab + Azathioprine with Placebo + Azathioprine (2 arms). Primary endpoint: Time to First Relapse at 4 years. Started Mar 2013; status: completed.
02
Drugs
belimumab
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT01663623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01663623.